Status:
COMPLETED
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.
Eligibility Criteria
Inclusion
- First kidney transplantation
- Male and female patients
- Between 18 and 65 years old
Exclusion
- Patients in need of multiple organ transplants
Key Trial Info
Start Date :
May 7 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 19 2005
Estimated Enrollment :
696 Patients enrolled
Trial Details
Trial ID
NCT00099736
Start Date
May 7 2003
End Date
September 19 2005
Last Update
August 22 2017
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85054
2
Los Angeles, California, United States, 90057
3
Palo Alto, California, United States, 94303
4
San Francisco, California, United States, 94143